Pneumococcal infections - Pipeline Insight, 2021

May 2021 | 60 pages | ID: P610E252724EEN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Pneumococcal infections – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pneumococcal infections Understanding

Pneumococcal infections: Overview

Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections – these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections – these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.

'Pneumococcal infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.

Pneumococcal infections Emerging Drugs Chapters

This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumococcal infections Emerging Drugs

• 20-Valent Pneumococcal Conjugate Vaccine: Pfizer

On September 20, 2018, Pfizer announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for 20vPnC for the prevention of invasive disease and pneumonia in adults age 18 years or older. The 20vPnC vaccine candidate consists of capsular polysaccharide conjugates for the 13 serotypes included in Prevnar 13 (Pfizer), along with 7 additional serotypes that cause invasive pneumococcal disease. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for the 20-valent pneumococcal conjugate vaccine (20vPnC) candidate (Pfizer) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults aged 18 years and older.

• V 114: Merck sharp & Dohme

V114 is Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease in adults. V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease. V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older. The U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The European Medicines Agency is also reviewing an application for licensure of V114 in adults.

Further product details are provided in the report

Pneumococcal infections: Therapeutic Assessment

This segment of the report provides insights about the different Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pneumococcal infections

There are approx. 15+ key companies which are developing the therapies for Pneumococcal infections. The companies which have their Pneumococcal infections drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.

Pneumococcal infections Report Insights

• Pneumococcal infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumococcal infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumococcal infections drugs?
• How many Pneumococcal infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumococcal infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Contents

Introduction
Executive Summary
Pneumococcal infections: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Pneumococcal infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Pneumococcal infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pneumococcal infections Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
  Comparative Analysis
20-Valent Pneumococcal Conjugate Vaccine: Pfizer
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
  Comparative Analysis
LBVE 013: LG Life Sciences
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
  Comparative Analysis
EuPCV15:EuBiologics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report
Inactive Products
  Comparative Analysis
Pneumococcal infections Key Companies
Pneumococcal infections Key Products
Pneumococcal infections- Unmet Needs
Pneumococcal infections- Market Drivers and Barriers
Pneumococcal infections- Future Perspectives and Conclusion
Pneumococcal infections Analyst Views
Pneumococcal infections Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Pneumococcal infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Pneumococcal infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products